The acquisition adds a potential rare disease asset to Sanofi’s alpha-1 antitrypsin deficiency pipeline.
TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com
On Jan, 23, 2024, Sanofi announced its planned acquisition of Inhibrx, a clinical-stage biopharmaceutical, in a deal valued at approximately $1.7 billion with a potential additional cash consideration of around $296 million. The acquisition will take place after the spin-off of non-INBRX-101 assets, such as its immune-oncology pipeline, into New Inhibrx. New Inhibrx will also retain its employees.
INBRX-101 is a human recombinant protein that can potentially normalize serum alpha-1-antitrypsin (AAT) levels in AAT deficiency (AATD) patients with less frequent doses. AATD is a genetic rare disease defined by low levels of AAT protein, which primarily affects the lung with progressive deterioration of the tissue. INBRX-101 works by inhibiting neutrophil elastase, an enzyme that causes lung tissue damage in AATD patients. INBRX-101 has the potential to reduce inflammation and prevent further deterioration of lung function in affected patients, according to a company press release.
INBRX-101 has finished a Phase I trial, where it demonstrated positive results in terms of safety and pharmacokinetics. It is being enrolled in a Phase II clinical trial to continue evaluating its potential as a treatment for AATD.
“The addition of INBRX-101 as a high-potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products,” said Houman Ashrafian, head of Research and Development at Sanofi, in the press release. “With our expertise in rare diseases and growing presence in immune-mediated respiratory conditions, INBRX-101 will complement our approach to deploy R&D efforts in key areas of focus and address the needs of the underserved AATD patients and communities.”
Source: Sanofi
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.